| Literature DB >> 33516392 |
Roddy Hiram1, Steeve Provencher2.
Abstract
Atrial fibrillation is associated with aging, obesity, heart disease, diabetes, and/or hypertension. Recent evidence suggests that parenchymal and vascular lung diseases increase atrial fibrillation risk. We review the epidemiology, clinical features, pathophysiologic mechanisms, and treatment implications of atrial fibrillation associated with diseases of the lungs and their vasculature, especially pulmonary hypertension. We also consider other features of pulmonary disease-associated atrial fibrillation. A key mediator of these conditions is right heart disease and right atrial remodeling. We pay particular attention to the pathophysiology and treatment challenges in atrial fibrillation associated with right heart disease induced by pulmonary diseases, including pulmonary hypertension.Entities:
Keywords: Antiarrhythmic therapy; Atrial fibrillation; Chronic lung diseases; Pulmonary hypertension; Right atrial remodeling; Right heart disease
Year: 2021 PMID: 33516392 DOI: 10.1016/j.ccep.2020.10.001
Source DB: PubMed Journal: Card Electrophysiol Clin ISSN: 1877-9182